Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAthelney Tst. Regulatory News (ATY)

Share Price Information for Athelney Tst. (ATY)

Share Price is delayed by 15 minutes
Get Live Data
165.00    0.00 (0.00%)
Bid:
140.00
Ask:
190.00
Spread: 50.00 (35.714%)
Market Cap: £3.56m
ATY Live PriceLast checked at - London Stock Exchange

Intraday Athelney Tst. Share Chart

Net Asset Value(s)

7 Apr 2026 07:00

RNS Number : 3477Z
Athelney Trust PLC
03 April 2026
 

 

Athelney Trust PLC

 

Legal Entity Identifier:

213800ON67TJC7F4DL05

The unaudited net asset value of Athelney Trust was 157.4p at 31 March 2026.

Fund Manager's comment for March 2026

The US economy grew by 2.0% year-on-year in the fourth quarter of 2025, slightly below the previous quarter's 2.3%, with recent business surveys suggesting the economy continues to expand albeit at a slower pace. Inflation stayed contained, with CPI at 2.4% in February. Manufacturing activity strengthened, supported by improving new orders, while services growth slowed modestly as softer demand and geopolitical uncertainty weighed on business sentiment.

The Euro Area economy grew by 1.2% in the fourth quarter of 2025, marking the slowest pace of growth in over a year. While manufacturing activity improved due to increased exports, services activity slowed.

The UK economy only grew by 1.0% year-on-year in the fourth quarter of 2025, slowing from 1.3% in the previous quarter. Production rebounded modestly while services growth eased. Inflation remained at 3.0%, with the Bank of England keeping interest rates at 3.75%. Recent business surveys suggest economic activity continues to expand, although at a slower pace.

In March, global equities were negatively impacted by the conflict in the Middle East. The MSCI World Index fell 6.6%, the S&P 500 by 5.1% and Nasdaq down by 4.8%. UK equities were also hit with the FTSE 100 down 6.7%, and Small Cap and AIM indices falling 10.3% and 12.5% respectively. While the conflict is expected to be short term, the markets concern is related to the longer-term impact of supply constraints and higher prices for oil and gas supplies to Europe and Asia.

These concerns led to a sharp rise in UK 10-year gilt yields to as high as 4.9% during the month, edging toward their highest level since 2008. Higher long-term interest rates typically place pressure on valuations, particularly for smaller growth companies whose earnings are expected further into the future. As a result, our portfolio performance was impacted by the conflict in the Middle East and the expectations of higher interest rates but not to the same extent, with the portfolio NAV decreasing by 7.79% for the month, after allowing for all fees and expenses. During the month, we added to our holding in MONY Group and trimmed our holding in Impax Asset Management.

Many portfolio companies reported results or trading updates during March. Boku delivered strong Full Year results with revenue up 30% and adjusted EBITDA up 36%. Medium‑term guidance remained unchanged with >20% organic revenue growth and adjusted EBITDA margin >30%.

Fever-Tree Full Year results showed brand revenue rose 4% YoY (H2 +5%). The US partnership with Molson Coors preserved brand momentum. Liontrust will acquire River Global Holdings in an all‑share deal, adding £2.722bn in AUM, India strategies and experienced managers. PayPoint expects a record FY26 broadly in line with expectations including growing dividends.

Raspberry PI reported Full year revenue of $323m, up 25% YoY with gross profit up 23%. Management expects materially higher revenue and profitability in line with market estimates for 2026. Spectra reported FY2025 revenue of $64.3M, up +30.7%, with adjusted EBITDA of $27.3M, up 82.9%. The dividend was increased by 17% to $0.136/share.

The largest contributors to performance during the month were AJ Bell, Spectra Systems and Raspberry PI while AEW UK Reit, Dunelm and FeverTree were the largest detractors from performance.

 

Fact Sheet

An accompanying fact sheet which includes the information above as well as wider details on the portfolio can be found on the Fund's website www.athelneytrust.co.uk under "About" then select "Latest Monthly Fact Sheet".

Background Information

Dr. Emmanuel (Manny) Pohl AM

Manny is Chairman and Chief Investment Officer of E C Pohl & Co ("ECP"), an investment management company and has been a major shareholder in Athelney trust for many years.

E C Pohl & co is licensed by the Australian Financial services (license no.421704).

www.ecpohl.com

www.ecpam.com

Manny Pohl and the ECP group has AUD2.7bn (£1.5 billion) under its management including four listed investment companies, three listed in Australia and one in the UK:

· Flagship Investments (ASX code:FSI)

 https://flagshipinvestments.com.au

· ECP Emerging Growth (ASX code: ECP)

 https://ecpam.com/emerging

· Global Masters Fund Limited (ASX code: GFL)

 www.globalmastersfund.com.au

· Athelney Trust plc (LSE code: ATY)

 www.athelneytrust.co.uk

Athelney Trust plc Investment Policy

 The investment objective of the Trust is to provide shareholders with prospects of long-term capital growth with the risks inherent in small cap investment minimised through a spread of holdings in quality small cap companies that operate in various industries and sectors. The Fund Manager also considers that it is important to maintain a progressive dividend record.

The assets of the Trust are allocated predominantly to companies with either a full listing on the London Stock Exchange or a trading facility on AIM or ISDX. The assets of the Trust have been allocated in two main ways: first, to the shares of those companies which have grown steadily over the years in terms of profits and dividends but, despite this progress, the market rating is favourable when compared to future earnings and dividends; second, to those companies whose shares are standing at a favourable level compared with the value of land, buildings or cash in the balance sheet.

Athelney Trust was founded in 1994. In 1996 it was one of the ten pioneer members of the Alternative Investment Market ("AIM"). In 2008 the shares became fully listed on the main market of the London Stock Exchange. Athelney Trust has a successful progressive dividend growth record and the dividend has grown every year since 2004. According to the Association of Investment Companies (AIC) Athelney Trust is a "Dividend Hero" being one of only a few investment companies that have increased their dividend every year for 20 years or more. See link

https://www.theaic.co.uk/income-finder/dividend-heroes

Website

www.athelneytrust.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGIGDSXSGDGLX
Date   Source Headline
3rd Jun 20267:22 amRNSNet Asset Value(s)
6th May 20267:35 amRNSNet Asset Value(s)
16th Apr 20268:50 amRNSAGM Statement
7th Apr 20267:00 amRNSNet Asset Value(s)
3rd Mar 20263:15 pmRNSAnnual Financial Report
3rd Mar 202612:09 pmRNSNet Asset Value(s)
3rd Feb 20268:27 amRNSNet Asset Value(s)
5th Jan 20269:53 amRNSNet Asset Value(s)
2nd Dec 202510:41 amRNSNet Asset Value(s)
4th Nov 202511:01 amRNSNet Asset Value(s)
10th Oct 20252:27 pmRNSAuditor change
9th Oct 20254:08 pmRNSNet Asset Value(s)
3rd Oct 20257:02 amRNSNet Asset Value(s)
2nd Sep 20259:09 amRNSNet Asset Value(s)
4th Aug 202510:48 amRNSNet Asset Value(s)
25th Jul 20257:00 amRNSHalf-year Report
3rd Jul 20257:00 amRNSNet Asset Value(s)
3rd Jun 202512:08 pmRNSNet Asset Value(s)
6th May 20258:59 amRNSNet Asset Value(s)
24th Apr 20257:11 amRNSResult of the AGM
2nd Apr 20259:38 amRNSNet Asset Value(s)
11th Mar 20254:15 pmRNSAnnual Financial Report
4th Mar 202512:03 pmRNSNet Asset Value(s)
5th Feb 20258:01 amRNSNet Asset Value(s)
6th Jan 202510:25 amRNSNet Asset Value(s)
3rd Dec 20248:21 amRNSNet Asset Value(s)
4th Nov 20247:53 amRNSNet Asset Value(s)
10th Oct 20248:13 amRNSAuditor Appointment
3rd Oct 20241:29 pmRNSNet Asset Value(s)
4th Sep 20249:46 amRNSNet Asset Value(s)
16th Aug 20242:21 pmRNSChange of Adviser
2nd Aug 20247:46 amRNSNet Asset Value(s)
24th Jul 20242:03 pmRNSHalf-year Report
2nd Jul 202411:59 amRNSNet Asset Value(s)
6th Jun 20247:00 amRNSNet Asset Value(s)
7th May 20249:54 amRNSNet Asset Value(s)
4th Apr 20249:21 amRNSNet Asset Value(s)
22nd Mar 20248:15 amRNSAGM Statement
5th Mar 20242:04 pmRNSNet Asset Value(s)
13th Feb 202411:58 amRNSDividend Declaration
5th Feb 202410:17 amRNSNet Asset Value(s)
3rd Jan 202411:13 amRNSNet Asset Value(s)
5th Dec 20232:45 pmRNSNet Asset Value(s)
6th Nov 20237:00 amRNSNet Asset Value(s)
20th Oct 20237:29 amRNSAuditor appointment
10th Oct 202310:54 amRNSChange of Adviser
4th Oct 20232:58 pmRNSNet Asset Value(s)
4th Sep 202311:17 amRNSNet Asset Value(s)
2nd Aug 20239:06 amRNSNet Asset Value(s)
25th Jul 202311:37 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.